CatalystAlert

Search CatalystAlert

Search for companies, drugs, and catalysts

Search CatalystAlert

Search for companies, drugs, and catalysts

Endpoints News
Original article

Amgen cans its TScan partnership; Amylyx reveals $350M offering

PartnershipNegative
AI Analysis

Summary

Amgen terminated its partnership with TScan Therapeutics, a T cell therapy company. Amylyx announced a $350M offering.

Outcome Details

Partnership termination

Importance:6/10
Sentiment:
-0.40
partnership_terminationofferingT_cell_therapy
Related Companies

Read the original article

Published by Endpoints News on August 19, 2026 2:43 PM

Read Original